Cite
Study of p53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus.
MLA
Kaneko, K., et al. “Study of P53 Gene Alteration as a Biomarker to Evaluate the Malignant Risk of Lugol-Unstained Lesion with Non-Dysplasia in the Oesophagus.” British Journal of Cancer, vol. 96, no. 3, Feb. 2007, pp. 492–98. EBSCOhost, https://doi.org/10.1038/sj.bjc.6603582.
APA
Kaneko, K., Katagiri, A., Konishi, K., Kurahashi, T., Ito, H., Kumekawa, Y., Yamamoto, T., Muramoto, T., Kubota, Y., Nozawa, H., Makino, R., Kushima, M., & Imawari, M. (2007). Study of p53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus. British Journal of Cancer, 96(3), 492–498. https://doi.org/10.1038/sj.bjc.6603582
Chicago
Kaneko, K., A. Katagiri, K. Konishi, T. Kurahashi, H. Ito, Y. Kumekawa, T. Yamamoto, et al. 2007. “Study of P53 Gene Alteration as a Biomarker to Evaluate the Malignant Risk of Lugol-Unstained Lesion with Non-Dysplasia in the Oesophagus.” British Journal of Cancer 96 (3): 492–98. doi:10.1038/sj.bjc.6603582.